Comparative Pharmacology
Head-to-head clinical analysis: BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE versus METAHYDRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE versus METAHYDRIN.
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE vs METAHYDRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisoprolol is a cardioselective beta-1 adrenergic receptor antagonist that reduces heart rate and myocardial contractility, decreasing cardiac output. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium-chloride symporter in distal convoluted tubule, reducing plasma volume.
Metahydrin (trichlormethiazide) is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and increasing excretion of water, sodium, chloride, and potassium.
One tablet orally once daily. Initial dose: 2.5 mg/6.25 mg to 10 mg/25 mg, titrated based on response. Maximum: 20 mg/50 mg per day.
Oral, 50-100 mg once daily. Maximum 200 mg/day.
None Documented
None Documented
Bisoprolol: terminal half-life 10-12 hours (up to 15 hours in elderly/clinically significant for once-daily dosing); Hydrochlorothiazide: terminal half-life 6-15 hours (prolonged in renal impairment).
18-30 hours (clinically relevant for once-daily dosing in hypertension; prolonged in renal impairment)
Bisoprolol: 50% unchanged in urine, remainder as inactive metabolites; Hydrochlorothiazide: 95% unchanged in urine. Fecal elimination: negligible.
Renal: 30% (fecal: 70% as unabsorbed drug, primarily biliary elimination; <1% unchanged in urine)
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic